Project Grant R01AG093010
Award Date
6/1/25
Completion Date
3/31/30
Dollars Obligated
$589K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $816,554 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to The University of Texas MD Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) associated with colorectal cancer. The project aims to assess the impact of surgery and tumor growth on the subsequent development of sustained pain hypersensitivity in response to an...
This federal Project Grant award of $5,666,172 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to understand the role of Schwann cells and their PPARG and LRP1 signaling pathways in chemotherapy-induced painful peripheral neuropathy (CIPPN). The key products and services to be delivered under this 5-year grant include: 1) examining the effects of PPARG and LRP1 on Schwann cell survival,...
This $661,122 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of Columbia University in the City of New York aims to investigate the pathogenic role of tubulin post-translational modifications in chemotherapy-induced peripheral neuropathy (CIPN). The project will evaluate whether the accumulation of delta-2 tubulin, an irreversible modification, plays a common pathogenic role in the neuropathic damage caused by various...
This federal Project Grant award of $450,313.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research by The Johns Hopkins University to investigate the potential of MAP4K4 inhibition to prevent chemotherapy-induced peripheral neuropathy (CIPN). The researchers will test the hypothesis that inhibiting the MAP4K4 protein can protect peripheral...
This National Cancer Institute (NCI) Project Grant award under the Cancer Treatment Research program (CFDA 93.395) provides $402,874 in funding to the University of Texas Medical Branch at Galveston (UTMB) from September 1, 2024 to August 31, 2029. The project aims to identify the molecular and cellular mechanisms by which the chemotherapy drug paclitaxel acutely excites sensory neurons, leading to the development of paclitaxel-induced peripheral neuropathy (PIPN) in cancer patients. The...
This $181,448 Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University (VCU) to investigate the use of the NLRP3 inflammasome inhibitor dapansutrile for treating chemotherapy-induced peripheral neuropathy (CIPN). The project aims to determine if dapansutrile can alleviate and prevent CIPN caused by paclitaxel and cisplatin chemotherapy in mouse models, including both naive and tumor-bearing animals. Researchers...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $426,960 to Wake Forest University Health Sciences to conduct research on the contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy (CIPN). The key objective of this 2-year study is to characterize the neuro-immune interactions in the skin of tumor-bearing mice with oxaliplatin-induced peripheral neuropathy...
The National Institute on Aging (NIA) awarded a $388,750 Project Grant (CFDA 93.866 - Aging Research) to The Washington University in St. Louis to conduct research on the role of senescent cancer-associated fibroblasts (SenCAFs) in breast cancer progression. The study aims to: 1) Determine the organ-specific effects of SenCAFs on metastatic breast cancer progression; 2) Examine how SenCAFs impact extracellular matrix dynamics and tumor cell migration; and 3) Assess the impact of SenCAFs on...
This Project Grant award, titled "Validation of Neuronal Senescence as a Target for Chronic Pain in Aging," is funded by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The total award of $2,249,392 is provided to The Leland Stanford Junior University to investigate age-related cellular senescence as a potential target for chronic pain treatment. The project aims to characterize the role of senescent...